Best Response

Didn't know they changed from Leerink Swann but they are a good firm in small-cap healthcare, lots of financings. From what I have seen, a decent amount have gone into MM PE, usually HC PE.

The phone interview is a typical interview, just know why Leerink or why HC.

 

shnningdown, I work for a boutique investment bank that also does a lot of deals in the biotech space but I am on the sales desk not a banker so take this with a grain of salt. But from what my bankers tell me when they are evaluating biotech deals especially when it comes to deals that in are the clinical trail stages with no revenues its all about management and their past deals. Also firms may hire outside biotech experts to review the science to see if the actually trials can be accomplished.

A good response to why healthcare/biotech is that without bankers finding deals and then the sales force finding clients retail/institutional that many of the best drugs out there would not be made. The majority of large pharma companies no longer do pre-clinical trials.

 

Possible question of how you would value a biotech firm with no revenue.

You could look at PV of peak sales, discount for risk of product not making it to the market or Discounted forward multiple method - try to capture value based upon expected growth from sales.

You cant do a DCF if the company has no real cash flow. Mostly would be revenue comps and the like.

Show an interest in HC, prep a stock just for safety but also check out the differences between different types of health care companies such biotech, life science, molecular diagnostics companies, etc, sometimes the lines can get a bit blurred but have a basic understanding would definitely help you stand out.

As for clinical trials trails, just understand the basic concepts, PI, PII, PII, they all can have extra arms, probablity of success increases PI-PIII.

Sorry for the ramblings. I hope I covered most of your questions.

 

@Carnage thank you so much!! This is actually really helpful.

As for a DCF couldn't you do a far into the future DCF and make cash flow projections based on market size and geography for the drug(s) a biotech firm has in more advanced clinical stages of its pipeline?

Also, I think you could do a sum of the parts valuation, with drugs that are in more advanced clinical stages being valued separately from drugs that are in earlier stages.

Thanks!

 

shiningdown - for clinical stage biotech, starting with market size (i.e. prevalence of indication / disease) and geography (though LP generally works with companies that are in trials in the US and most banks get EU/Asia revenue projections wrong anyways) is the correct way to do it. You then prescribe (ha) a discount rate based on probability of success (can use comps based on fda approvals or positive data readouts at each level, Ph I/II/III).... it's definitely not a science and even valuing companies that are just commercial but have a large pipeline can be difficult.

Drugs further along just have a lower discount rate than those in earlier stages and it's approximate based on whoever is guiding the model's experiences (or through physician interviews)

At the end of the day, showing interest in the industry is probably most key.

 

It's more art than science from my experience. You'll be looking at the market size, how crowded it is, and comps of companies that are further along in the process/had their IPO's already. There's just so much that can go differently than what you're expecting when you try to project further than 18-24 months (i.e. change in target demographic, business model, FDA regulations, etc.).

 
Grand Berry:

It's more art than science from my experience. You'll be looking at the market size, how crowded it is, and comps of companies that are further along in the process/had their IPO's already. There's just so much that can go differently than what you're expecting when you try to project further than 18-24 months (i.e. change in target demographic, business model, FDA regulations, etc.).

Completely agree it really is more of an art than a science when it comes to these companies. Have an understanding of the process behind those projections is really all you can bring to the table. Sounds like you are well on your way.

Good Luck.

 

Thanks for your reply about Leerink, I was curious if you have any experience in Healthcare banking? I have an interview with them coming up and was wondering what are some good sources of healthcare industry info that might be useful and/or healthcare specific valuation info. If not, no worries, but I would appreciate any feedback if you have any. Thanks again for your time

 

As for Healthcare IB, first try and study up on the different sub-sectors of healthcare, pharmaceuticals vs. home care vs. medical distribution vs. medtech and so on. Know what certain companies play in each space, i.e, like a McKesson in healthcare distribution, Walgreens in Retail Pharmacy or Medtronic and Siemens in Medtech.

Try and study up on healthcare terms/issues like medicare and medicaid stuff, reimbursement issues (a lot of these have happened or are happening), how a drug gets FDA approval, etc.

Because Leerink is focused solely on the healthcare space, they might grill you on healthcare specific things.

 

Definitely agree with dayaaam,

Healthcare can go from biotech/pharma, to assisted living, to REITs. All have different economics, and it is important to understand each individually, so that you can understand the rationales for M&A activity in each (if M&A is what you're in to). There's a large nonprofit factor in the healthcare space, too, so see if Leerink works in any of that.

 

read eq res reports on top life sciences and biologic companies, as well as generics (teva for ex) given the patent hill fall off over the next 3-4 yrs.

Leerink is heavy in LS, not so much on provider/payor space, although that is very active right now given ACO regulation and the insolvencies within the providor space.

 

Quis animi vel ratione ea eum. Dolor vel sit qui eum rerum. Sit reiciendis sint nam animi. Sapiente aut nostrum occaecati praesentium sit quam sunt.

Doloremque eligendi accusamus ut voluptatem est. Fugit ducimus dolores beatae ut rerum beatae ex et. Inventore aut in quam aut. Error saepe qui incidunt dolores repudiandae. Eos odio et maiores ex veniam enim quam repudiandae.

Nobis maxime facilis iure. Repellat laboriosam dolore quia aut qui. Dicta magnam fuga dolorem.

Officiis minima repellat aut quaerat nobis. Deleniti adipisci hic dolor quia. Sit exercitationem repellendus dolorem voluptas porro possimus natus. Et magni assumenda beatae quo. Occaecati eos eos quod in omnis ratione neque. Saepe est ut deserunt quaerat.

 

Recusandae eum eveniet officiis nostrum repellat. Amet dolore voluptas magnam repellendus cum id. Magnam sunt nesciunt quam laudantium quam voluptate. Quos voluptatum odio non exercitationem iusto non quam.

Sunt vel culpa natus veniam corrupti voluptas nulla. Porro laborum magnam odio est. Perferendis odio voluptatem consectetur qui officiis quo rerum.

Eveniet ipsam culpa hic in in officia cum. Similique debitis nihil ut voluptatem. Dolores error voluptas dolores rem est.

"Jesus, he's like a gremlin; comes with instructions and shit"

Career Advancement Opportunities

March 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. (++) 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

March 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

March 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

March 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (13) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (202) $159
  • Intern/Summer Analyst (144) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Betsy Massar's picture
Betsy Massar
99.0
5
dosk17's picture
dosk17
98.9
6
CompBanker's picture
CompBanker
98.9
7
kanon's picture
kanon
98.9
8
GameTheory's picture
GameTheory
98.9
9
DrApeman's picture
DrApeman
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”